OAC
TARA icon

OMERS Administration Corp’s Protara Therapeutics TARA Stock Holding History

OMERS Administration Corp’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75,100
Closed -$320K – 1081
2025
Q1 		$320K Buy
+75,100
New +$335K ﹤0.01% 846

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OMERS Administration Corp's TARA Position: Q2 2025 in Review

OMERS Administration Corp sold out of Protara Therapeutics (TARA) in Q2 2025, closing a stake of 75,100 shares — an estimated $320K sold.

OMERS Administration Corp first reported a position in TARA in Q1 2025 and held it in 1 quarter. The position peaked at $320K in Q1 2025. 76 funds tracked by Wall St. Rank hold TARA as of Q2 2025.

  • OMERS Administration Corp reported no remaining Protara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 75,100 Protara Therapeutics shares in Q2 2025, an estimated $320K.
  • OMERS Administration Corp first reported a position in Protara Therapeutics in Q1 2025 and held it in 1 quarter.
  • OMERS Administration Corp's Protara Therapeutics position peaked at $320K in Q1 2025.
  • 76 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.